clinical trial · NCT06320080
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase1·terminated·n = 22
Advanced Hepatocellular CarcinomaTQB2223 injectionPenpulimab Injection
brief summary
TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. This is a phase Ib study aimed at evaluating the safety, tolerability, and immunogenicity characteristics of TQB2223 injection combined with AK105 injection in the treatment of advanced hepatocellular carcinoma.
started
May 30, 2024
primary completion
Nov 3, 2025
completion
Nov 3, 2025
last updated
Nov 21, 2025
official title
Phase Ib Clinical Study Evaluating the Efficacy and Safety of TQB2223 Injection Combined With Penpulimab Injection in the Treatment of Advanced Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol